GSK/Adolor To Begin New Phase III Entereg Trial In Opioid-Induced Bowel Dysfunction
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies also anticipate submitting “complete response” to FDA for postoperative ileus indication in second quarter.
You may also be interested in...
FDA Accepts Adolor/GSK Entereg Resubmission For Postoperative Ileus
Sponsors’ response to FDA clinical holds on the alvimopan program contain “substantially the same” information as the resubmitted NDA, Adolor tells “The Pink Sheet” DAILY.
FDA Accepts Adolor/GSK Entereg Resubmission For Postoperative Ileus
Sponsors’ response to FDA clinical holds on the alvimopan program contain “substantially the same” information as the resubmitted NDA, Adolor tells “The Pink Sheet” DAILY.
GlaxoSmithKline/Adolor Halt Entereg Bowel Dysfunction Program Due To Cardiovascular Events
Top-line, 12-month Phase III safety data underscore CV concerns and raise new adverse event questions.